The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer (JBCRG-M08; AMBER study).
 
Tetsuhiro Yoshinami
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Lilly; MSD; Pfizer
 
Shinsuke Sasada
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Nipro Corporation (Inst)
 
Meiko Nishimura
No Relationships to Disclose
 
Madoka Iwase
No Relationships to Disclose
 
Chiya Oshiro
No Relationships to Disclose
 
Kaori Terata
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichikyo; Pfizer
 
Mikiya Ishihara
Honoraria - AstraZeneca/Daiichi Sankyo; Chugai Pharma; Eisai; Kyowa Kirin International; MSD; Nihonkayaku; Ono Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
 
Hiroko Bando
Speakers' Bureau - AstraZeneca; Chugai Pharma; DAllCHl SANKYO; Kyowa Kirin; Lilly; MSD; Pfizer
 
Masahiko Tanabe
No Relationships to Disclose
 
Nobuyasu Yoshimoto
No Relationships to Disclose
 
Sayuri Akiyoshi
No Relationships to Disclose
 
Masahiro Takada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical
Research Funding - ABSCG (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Guardant Health (Inst); IQVIA (Inst); JBCRG (Inst); KBCRN (Inst); Medbis (Inst); Yakult Pharmaceutical (Inst)
 
Hiroshi Ishiguro
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Mitsubishi Tanabe Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Nipro Corporation (Inst); Takeda (Inst)
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Kyowa Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin; MSD; Roche/Genentech
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer
Research Funding - Eisai (Inst)
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group; Japan Society of Clinical Oncology (JSCO); Japanese Breast Cancer Society
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Gilead Sciences; Kyowa-Kirin; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono-Pharma (Inst); Pfizer (Inst); Sanofi (Inst)